S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.27 (+1.25%)
BABA   74.88 (+0.28%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.26 (-3.12%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.07%)
GE   121.80 (+2.47%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.25%)
PFE   30.47 (+1.30%)
PYPL   57.61 (-0.62%)
XOM   102.74 (+0.39%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.27 (+1.25%)
BABA   74.88 (+0.28%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.26 (-3.12%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.07%)
GE   121.80 (+2.47%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.25%)
PFE   30.47 (+1.30%)
PYPL   57.61 (-0.62%)
XOM   102.74 (+0.39%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.27 (+1.25%)
BABA   74.88 (+0.28%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.26 (-3.12%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.07%)
GE   121.80 (+2.47%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.25%)
PFE   30.47 (+1.30%)
PYPL   57.61 (-0.62%)
XOM   102.74 (+0.39%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.27 (+1.25%)
BABA   74.88 (+0.28%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.26 (-3.12%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.07%)
GE   121.80 (+2.47%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.25%)
PFE   30.47 (+1.30%)
PYPL   57.61 (-0.62%)
XOM   102.74 (+0.39%)

Monopar Therapeutics (MNPR) Stock Forecast & Price Target

$0.29
-0.01 (-4.76%)
(As of 05:22 PM ET)
Compare
Today's Range
$0.29
▼
$0.32
50-Day Range
$0.29
▼
$0.60
52-Week Range
$0.27
▼
$3.82
Volume
105,717 shs
Average Volume
417,471 shs
Market Capitalization
$4.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Monopar Therapeutics Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$13.00
4,381.21% Upside
High Forecast$24.00
Average Forecast$13.00
Low Forecast$2.00
TypeCurrent Forecast
11/30/22 to 11/30/23		1 Month Ago
10/31/22 to 10/31/23		3 Months Ago
9/1/22 to 9/1/23		1 Year Ago
11/30/21 to 11/30/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.00$11.33$11.33$7.00
Predicted Upside4,381.21% Upside341.35% Upside341.35% Upside225.08% Upside
Get Monopar Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.


MNPR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MNPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Monopar Therapeutics Stock vs. The Competition

TypeMonopar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside4,381.21% Upside907.34% Upside4,719.28% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/15/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$6.00 ➝ $2.00+113.90%
3/29/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
3/24/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$24.00+773.61%
12/9/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
(Data available from 11/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MNPR Price Target - Frequently Asked Questions

What is Monopar Therapeutics's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Monopar Therapeutics stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for MNPR. The average twelve-month price prediction for Monopar Therapeutics is $13.00 with a high price target of $24.00 and a low price target of $2.00. Learn more on MNPR's analyst rating history.

Do Wall Street analysts like Monopar Therapeutics more than its competitors?

Analysts like Monopar Therapeutics more than other Medical companies. The consensus rating score for Monopar Therapeutics is 2.75 while the average consensus rating score for medical companies is 2.67. Learn more on how MNPR compares to other companies.

Does Monopar Therapeutics's stock price have much upside?

According to analysts, Monopar Therapeutics's stock has a predicted upside of 415.90% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MNPR) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -